返回
摘要
En 中文
Tumour metastasis, the movement of tumour cells from a primary site to progressively colonize distant organs, is a major contributor to the deaths of cancer patients. Therapeutic goals are the prevention of an initial metastasis in high-risk patients, shrinkage of established lesions and prevention of additional metastases in patients with limited disease. Instead of being autonomous, tumour cells engage in bidirectional interactions with metastatic microenvironments to alter antitumour immunity, the extracellular milieu, genomic stability, survival signalling, chemotherapeutic resistance and proliferative cycles. Can targeting of these interactions significantly improve patient outcomes? In this Review preclinical research, combination therapies and clinical trial designs are re-examined.
Keyword:
BREAST-CANCER CELLS
ENDOTHELIAL GROWTH-FACTOR
KINASE INHIBITOR SARACATINIB
RANDOMIZED PHASE-II
OXALIPLATIN-BASED CHEMOTHERAPY
PROSTATE-CANCER
TGF-BETA
COLORECTAL-CANCER
BRAIN METASTASIS
MYELOID CELLS
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
66.8
论文数:
3.8K
被引数:
6.0W
机构
引用论文
A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma
ONCOGENE
IF7.3
Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo
CLINICAL CANCER RESEARCH
IF10.2
End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma
NEURO-ONCOLOGY
IF13.4

